THE CRAVE OF FIXED DOSE COMBINATION IN INDIAN MARKET

Authors

  • BALASUBRAMANIAN J
  • RADHIKA N
  • BADARINATH AV

Abstract

The aim of the present retrospective works reveals the need of fixed-dose combination (FDC) in Indian market as per the Indian regulations.
A combination drug most commonly refers to an FDC, which is a formulation including two or more active pharmaceutical ingredients combined in
a single dosage form, which is manufactured and distributed in certain respective fixed doses. This review outlines the FDCs rationale, guidelines on
data required for approval for marketing FDCs, marketing potential throughout the world. The safety of the combination drugs has to be thoroughly
evaluated, and there are considerations for the drugs that are already in the market as individual or single-drug entity. However, the safety profile of
the established drugs will alter when they are combined together. However, many of the irrational combinations are popular and widely prescribed
by physicians in our country. This study provides a comprehensive analysis of the current markets for FDC products throughout the world and the
market potential of promising drugs under development.

Keywords: Fixed dose combinations, Active pharmaceutical ingredients, Human immunodeficiency virus, Chronic obstructive pulmonary disease,
World Health Organization, Non-steroidal anti-inflammatory.

Downloads

Download data is not yet available.

References

Lori Tucker, Donald Saxman, Anna Welch Crull. The Global Market For

Fixed –Dose Combination Drugs for Leading Diseases. Available from:

http://www.stix-market-research.com/stix publications/combinational

drugs.html. [Last accessed 2013 Dec ???].

Christopher Comfort. The COPD Drug Market Will Become More

Fractured As Several New Agents Reach The Market And Erode The

Dominance Of The Current Market Leaders.Available from: http://

www.decisionresources.com/News-and-Events/Press-Releases/COPD-

[Last accessed 2012 Oct 9].

Julie McKenna. COPD Tops Asthma as the Focus Indication for

Next Generation Respiratory Therapies at the 2012 American

Thoracic Society Conference. Available from: http://www.photos.

prnewswire.com/prnh/20120531/NE16127-INFO. [Last accessed

May 21].

BoehringerIngelheim to present highly anticipated Phase III data in IPF

and COPD at ATS International Conference, last accessed April 30,

Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters

such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion.

Available from: http://www.asdreports.com/ASDR-9495. [Last

accessed 2012 Mar ???].

Katherine L. Combination therapy in hypertension management. US

Pharm 2012;37(6):46-50.

FIXED-DOSE COMBINATIONS - Fixed-Dose Combination Products

– A Review. Available from: http://www.drug-dev.com/Main/Back-

Issues/FIXEDDOSE-COMBINATIONS-FixedDose-Combination-

Produ-673. [Last accessed 2014 Apr ???].

Collier R. Reducing the pill burdenâ€. CMAJ 2012;184(2):E117-8.

Blomberg B, Spinaci S, Fourie B, Laing R. The rationale for

recommending fixed-dose combination tablets for treatment of

tuberculosis. Bull World Health Organ 2001;79(1):61-8.

Ellard GA, Fourie PB. Rifampicin bioavailability: A review of its

pharmacology and the chemotherapeutic necessity for ensuring optimal

absorption. Int J Tuberc Lung Dis 1999;3 11 Suppl 3:S301-8.

Narendranath KG. Ban or curb on major fixed dose combinations

imminent, many anti-epileptic and mucolytic – antibiotics preparations

under critical review, 2000.

Sweetman SC. Martindale: The Complete Drug Reference. 33rd ed.

London: Pharmaceutical Press; 2002. p. 205-6, 215-7, 240-1.

Kaplan W. Fixed dose Combinations as an Innovative Delivery

Mechanism. Background papers to this are Available from: archives.

who.int/priority meds/report background/delivery.doc. [Last accessed

Oct 7].

PharmaPoint: Alzheimer’s Disease – Global Drug Forecast and Market

Analysis to 2022. Available from: http://www.reportlinker.com/

P02029804/. [Last accessed 2013 Jul 31].

Kulkarni SK. On the safety of nimesulide, a preferential COX-2

inhibitor. Curr Sci 2000;83(12):1442-3.

Chakraborti A. Fixed dose combinations in therapy. Express Pharm

;2(19):62-3.

Gautam CS, Saha L. Fixed dose drug combinations (FDCs): Rational or

irrational: A view point. Br J Clin Pharmacol 2008;65(5):795-6.

John LJ, Devi P, John J, Guido S. Drug utilization study of antimicrobial

agents in medical intensive care unit of a tertiary care hospital. Asian J

Pharm Clin Res 2011;4(2):81-4.

Sengar MR, Gandhi SV, Patil UP, Rajmane VS. Simultaneous

determination of diclofenac sodium and thiocolchicoside in fixed

dose combination by spectrophotometry. Asian J Pharm Clin Res

;3(2):89-91.

Published

01-09-2014

How to Cite

J, B., R. N, and B. AV. “THE CRAVE OF FIXED DOSE COMBINATION IN INDIAN MARKET”. Asian Journal of Pharmaceutical and Clinical Research, vol. 7, no. 4, Sept. 2014, pp. 106-10, https://journals.innovareacademics.in/index.php/ajpcr/article/view/1498.

Issue

Section

Original Article(s)